Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:deliveredBy |
lipid nanoparticle
|
| gptkbp:developedBy |
gptkb:Verve_Therapeutics
|
| gptkbp:effect |
reduces LDL cholesterol
|
| gptkbp:firstInHumanTrial |
2022
|
| https://www.w3.org/2000/01/rdf-schema#label |
VERVE-101
|
| gptkbp:indication |
gptkb:heterozygous_familial_hypercholesterolemia
|
| gptkbp:mechanismOfAction |
base editing
|
| gptkbp:regionOfTrial |
gptkb:New_Zealand
gptkb:United_Kingdom |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:PCSK9_gene
|
| gptkbp:technology |
CRISPR base editing
|
| gptkbp:bfsParent |
gptkb:Verve_Therapeutics
|
| gptkbp:bfsLayer |
6
|